SYGGF

IFN-β (SNG001)

Chronic Obstructive Pulmonary Disease (COPD)

Phase 2 Data

Exp Date

TBA

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: IFN-β (SNG001) for COPD - Phase 2 Data

  • ClinicalTrial.gov (NCT03570359): A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza


WHAT IS THE CATALYST EVENT?

  • Phase 2 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBA


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION

  • Interferon beta is a naturally- occurring protein, which orchestrates the body’s antiviral responses. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility in ‘at-risk’ patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2 and MERS-CoV, have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells either prevents or greatly diminishes cell damage and viral replication, respectively. Synairgen’s SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action.

Updated by HC

SYGGF, Chronic Obstructive Pulmonary Disease (COPD), IFN-β (SNG001), lung disease

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

SYGGF - Data from SG016 Phase ...

Summary: Data published in the peer-reviewed journal shows positive results for SNG001 in hospitalised COVID-19 patients #SYGGF "announced the publication of data from the Company’s #SG016 trial in T...

SYGGF (Synairgen) - Positive ...

#SYGGF (Synairgen) announced "positive results from interim analysis of SG015, its double-blind placebo-controlled Phase II trial of SNG001 in COPD patients announced in September, supporting the COVI...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon